B cell
The immune cells that make antibodies. They matter in cancer twice over: as the source of every therapeutic antibody, and as the cells that go wrong in most lymphomas, leukaemias and myeloma.
Each B cell makes one antibody; when it meets its antigen it multiplies and matures into plasma cells that pump out that antibody in bulk, which is the response the hybridoma technique captured to make monoclonal antibodies. B cells carry surface markers (CD19, CD20, CD22) throughout their lives and plasma cells carry BCMA, and these markers make B-cell cancers (most lymphomas, CLL, ALL, myeloma) the most successful targets of rituximab, CAR-T and bispecific antibodies; since normal B cells are also wiped out, patients need antibody replacement and are prone to infection. B cells inside solid tumours, organised into structures resembling lymph nodes, are associated with better responses to immunotherapy.
Pages like this
not linked directly; found by shared links- TermAntigen
Shares Monoclonal, Immune system, Antibody, T cell.
- IdeaPlan the second CAR-T target before the first one is lost
Shares CD20, BCMA, CD19, Multiple myeloma.
- IdeaHospital-made CAR-T under one shared regulatory master file
Shares BCMA, CD19, Multiple myeloma, Acute lymphoblastic leukaemia.
- InstitutionUnion Hospital, Tongji Medical College
Shares BCMA, CD19, Multiple myeloma, Diffuse large B-cell lymphoma.
- InstitutionHadassah Medical Center
Shares BCMA, CD19, Multiple myeloma, Acute lymphoblastic leukaemia.
- IdeaHospital-based CAR-T manufacturing at cost through a public network
Shares BCMA, CD19, Multiple myeloma, Acute lymphoblastic leukaemia.
- PersonStanley R. Riddell
Shares CD19, Chronic lymphocytic leukaemia, Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma.
- TermLymph node
Shares Immune system, Lymphoma (tissue type), T cell.